

Multi-Drug Test Panel W/WO Adulteration (Urine) Product Insert

For laboratory in vitro diagnostic use only

INTENDED USE

The Rapid Response[™] Multi-Drug Test Panel (Urine) is a rapid chromatographic immunoassay for the qualitative and simultaneous detection of one to thirty of the following drugs in a variety of combinations in human urine. The designed cutoff concentrations and direct calibrator for these drugs are as follows:

Parameter	Calibrator	Cut-off(ng/mL)
ACE	Acetaminophen	5000
AMP	d-Amphetamine	1000/500/300
BAR	Secobarbital	300
BUP	BUP-3-D-Glucuronide	10/5
BZO	Oxazepam	500/300/200/100
COC	Benzoylecgonine	300/200/150/100
COT	(-)-Cotinine	600/300/200
EDDP	2-Ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine	300/100
ETG	Ethyl Glucuronide	500
FYL	Norfentanyl/Fentanyl	20/10
HMO	Hydromorphone	250
K2	JWH-073/JWH-018	50
KET	Ketamine	1,000/300
LSD	9,10-Didehydro-N,N-diethyl-6-methylergoline-8beta-carboxamide	50
6-MAM	6-Monoacetylmorphine	10
MDMA	3,4-Methylenedioxy-MET	1000/500
MET	Methamphetamine	1000/500/300
MOP	Morphine	300/200/100
MPD	Methylphenidate	1000/300
MQL	Methaqualone	300
MTD	Methadone	300/200
OPI	Morphine	2000/1000
OXY	Oxycodone	300/100
PCP	Phencyclidine	25
PPX	D-Propoxyphene	300
TCA	Nortriptyline	1000
THC	11-nor-△9-THC-9-COOH	300/200/150/50/25
TRA	Tramadol	300/100
ZOL	Zolpidem	50
Adulteration (Strip A) Oxidants / Specific G	ravity / pH

Adulteration (Strip B)

Oxidants / Specific Gravity / pH Nitrite / Glutaraldehyde /Creatinine

The DOA test is used to obtain visual qualitative result and is intended to assist in the determination of drug compliance.

This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC/MS) or Liquid Chromatography/ Mass Spectrometry (GC/MS) are the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

The Urine Adulteration Test Strips (Urine) are a semi-quantitative color comparison screen for the detection of Creatinine, Nitrite, Glutaraldehyde, pH, Specific Gravity, Oxidants and Pyridinium Chlorochromate in human urine. This test provides a preliminary screen only. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Abnormal results should be sent to a laboratory for confirmation.

PRINCIPLE

The Rapid Response™ Multi-Drug Test Panel (Urine) is one-step immunoassay in which chemically labeled drugs (drug-protein conjugates) compete for limited antibody binding sites with drugs which may be present in urine. The test membrane strips are pre-coated with drug-protein conjugates on the test band(s). For each strip, the drug antibody-colloidal gold conjugate pad is placed at one end of the membrane. In the absence of drug in the urine, the solution of the colored antibody-colloidal gold conjugate move along with the sample solution upward chromatographically by capillary action across the membrane to the immobilized drug-protein conjugate zone on the test band region. The colored antibody-gold conjugate then attach to the drug-protein conjugates to form visible lines as the antibody complex with the drug conjugate. Therefore, the formation of the visible precipitant in the test zone occurs when the test urine is negative for the drug. When the drug is present in the urine, the drug/metabolite antigen competes with drug-protein conjugate on the test band region for the limited antibody. When a sufficient concentration of the drug is present, it will fill the limited antibody binding sites. This will prevent attachment of the colored antibody-colloidal gold conjugate to the drug-protein conjugate zone on the test band region. Therefore, absence of the color band on the test region indicates a positive result.

A control band with a different antigen/antibody reaction is added to the immune-chromatographic membrane strip at the control region (C) to indicate that the test has performed properly. This control line should always appear regardless of the presence of drug or metabolite. If the control line does not appear the test strip should be discarded.

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause

false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine.

Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as Creatine, pH, and Specific Gravity and to detect the presence of Glutaraldehyde, Nitrite and Oxidants/Pyridinium Chlorochromate in urine.

Creatinine (CRE): Tests for specimen dilution. Creatinine is a waste product of Creatine, and is an amino-acid contained in muscle tissue and found in urine. A person may attempt to foil a drug test by drinking excessive amounts of water or diuretics such as herbal teas to flush the system. Creatinine and Specific Gravity are two ways to check for dilution and flushing, which are the most common mechanisms used to circumvent drug testing. Low Creatinine and Specific Gravity levels may indicate diluted urine. The absence of Creatinine (<5 mg/dL) is indicative of a specimen not consistent with human urine.

Nitrite (NIT): Tests for commonly used commercial adulterants. They work by oxidizing the major cannabinoid metabolite THC-COOH. Normal urine should contain no trace of Nitrites. Positive results generally indicate the presence of an adulterant. Glutaraldehyde (GLUT): Tests for the presence of aldehydes. Adulterants can contain Glutaraldehyde and can cause false negative screening results by disrupting the enzyme used in some immunoassay tests. Glutaraldehyde is not normally found in urine; therefore, detection of Glutaraldehyde in a urine specimen generally indicates adulteration.

pH: Tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate that the specimen has been altered.

Specific Gravity (SG): Tests for specimen dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

Oxidants/Pyridinium Chlorochromate (OXI/PCC): Tests for the presence of oxidizing reagents such as bleach and hydrogen peroxide. Pyridinium Chlorochromate is commonly used adulterant.³ Normal human urine should not contain Oxidants or PCC.

REAGENTS AND MATERIALS

Materials Provided

- Rapid Response™ Multi-Drug Test Panel (Urine)
- Adulteration Color Chart (when applicable)

Materials Required but Not provided

Product Insert

- Specimen collection container
- Positive and negative urine controls

PRECAUTIONS

- · For laboratory in vitro diagnostic use only.
- The pouch containing the test device should be sealed. Discard the test device if package is ripped or torn.
- · Urine specimens may be potentially infectious. Proper handling and disposal methods should be established.
- Avoid cross-contamination of urine samples by using a new specimen collection container and specimen pipette for each urine sample.

STORAGE AND STABILITY

The pouched Rapid Response™ Multi-Drug Test Panel (Urine) should be stored at normal humidity and room temperature or refrigerated (2-30°C; 36-86°F) until the expiration date stated on the pouch. The product is humidity-sensitive and should be used immediately after being opened. Any test in an improperly sealed pouch should be discarded.

SPECIMEN COLLECTION AND STORAGE

Urine Collection: The Rapid ResponseTM Multi-Drug Test Panel (Urine) is formulated for use with urine specimens. Fresh urine does not require any special handling or pretreatment. The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain clear specimen for testing.

Urine Storage: It is recommended the collected fresh urine to be tested immediately. Fresh urine maybe stored at room temperature (25°C; 77°F) for up to 4 hours or to be refrigerated (2-8°C; 36-86°F) for up to 48 hours prior to performing the test. For prolonged storage, specimens may be frozen and stored below -20°C (-4°F). Specimens that have been refrigerated must be brought to room temperature prior to testing. Previously frozen specimens must be thawed, brought to room temperature, and mixed thoroughly prior to testing.


Note: Urine specimens and all materials coming in contact with them should be handled and disposed of as if capable of transmitting infection. Avoid contact with skin by wearing gloves and proper laboratory attire.

PROCEDURE

IMPORTANT Test device, patient's sample, and controls should be brought to room temperature (15-30°C; 59-86°F) prior to testing. Do not open pouches until ready to perform the assay.

- 1. Remove the test device from the sealed pouch and use it as soon as possible.
- Dip the sample pad area of the dipstick strip or dipstick card in the urine specimen submerging only up to the "MAX" mark of the dipstick strip or the edge of the dipstick card.
- 3. For the adulteration tests, visually compare the color of the reaction pad with the color card, and the results should be read at 2 minutes. Do not interpret the results after 5 minutes.





4. The drug strip result(s) should be read at 5 minutes. However, negative results may be read and reported as early as 3 minutes but positive results must be reported at 5 minutes only. Do not interpret the drug strip result(s) after 10 minutes after the addition of sample.

INTERPRETATION OF RESULTS

C T

POSITIVE: Only one colored band appears, in the control region (C). No apparent colored band appears in the test region (T).



NEGATIVE: Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T).



INVALID: Control band fails to appear. Results from any test which has not produced a control band at the specified read time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

NOTE: 1. The intensity of color in the test region (T) may vary depending on the concentration of analytes present in the specimen. Therefore, any shade of color in the test region should be considered negative. Note that this is a qualitative test only, and cannot determine the concentration of analytes in the specimen. 2. Insufficient specimen volume, incorrect operating procedure or expired tests are the most likely reasons for control band failure.

The Result of Adulteration Strips: For specific color please reference the Adulteration Color Chart.

NOTE: The Urine Adulteration Test Strips (Urine) are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an all-inclusive representation of possible adulterants.

Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases show dilute urine. Nitritie: Nitrite is not a normal component of human urine. However, Nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of >20 mg/dL may produce false positive Glutaraldehyde results. Glutaraldehyde: Glutaraldehyde is not normally found in urine. However, certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high-protein diets) may interfere with the test results. Specific Gravity: Elevated levels of protein in urine may cause abnormally high Specific Gravity values. Oxidants/PCC: Normal human urine should not contain Oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the Oxidants/PCC pad.

OUALITY CONTROL

- Good laboratory practice recommends the use of control materials to ensure proper kit performance. Quality control specimens are available from commercial sources and are recommended to be used as per facilities quality control testing protocol. Use the same assay procedure as with a urine specimen. Controls should be challenging to the assay cutoff concentration. If control values do not fall within established limits, assay results are invalid. Users should follow the appropriate federal, state, and local guidelines concerning the running of external quality controls.
- The Rapid Response™ Multi-Drug Test Panel (Urine) provides built-in process control with a different antigen/antibody reaction at the control region (C) in each strip. This control line should always appear regardless of the presence of drug or metabolite. If the control line does not appear, the test device should be discarded. The presence of this control band in the control region serves as 1) verification that sufficient volume is added, 2) that proper flow is obtained.

LIMITATIONS OF THE TEST

- The Rapid Response™ Multi-Drug Test Panel (Urine) is for laboratory in vitro diagnostic use, and should be only used for the qualitative detection of drugs of abuse.
- 2. The assay is designed for use with human urine only.
- A positive result with any of the tests indicates only the presence of a drug/metabolite and does not indicate or measure intoxication.
- 4. There is a possibility that technical or procedural error as well other substances as factors not listed may interfere with the test and cause false results. See SPECIFICITY for lists of substances that will produce either positive results, or that do not interfere with test performance.
- If a drug/metabolite is found present in the urine specimen, the assay does not indicate frequency of drug use or distinguish between drug of abuse and certain foods and medicines.

PERFORMANCE CHARACTERISTICS

Accuracy Accuracy of the DOA Test Panels was established by running urine sample against GC/MS specification. The following results were tabulated:

% Agreement with GC/MS

Specimen	ACE	AMP1000	AMP500	AMP300	BAR	BUP10	BUP5	BZO500
Positive	96.1%	95.8%	95.9%	96.1%	97.8%	100%	100%	98%
Negative	100%	100%	100%	100%	98.1%	100%	100%	100%
Total	98.1%	98.1%	98.1%	98.1%	98%	100%	100%	99%

Specimen	BZO300	BZO200	BZO100	COC300	COC200	COC150	COC100	COT600
Positive	95.3%	97.4%	95.9%	98.2%	95.7%	96%	98.2%	96.5%
Negative	92.9%	98.2%	98%	98.1%	98.1%	94%	98.1%	98%
Total	93.9%	97.9%	97%	98.2%	97.0%	95%	98.2%	97.2%

Rev08-08042016 Number11110007865 Page 1 of 3

Specimen	COT300	COT200	EDDP300	EDDP100	ETG	FYL20	FYL10	HMO
Positive	97.9%	97.7%	98.6%	95.8%	100%	96.8%	94.4%	95.9%
Negative	98.1%	97.9%	100%	100%	100%	100%	100%	100%
Total	98%	98%	99.1%	98.1%	100%	98.3%	97.2%	98.0%

Specimen	K2	KET1000	KET300	LSD	6-MAM	MDMA	MDMA500	MET1000
Positive	98.9%	98%	98.3%	100%	96.8%	98.5%	100%	96.8%
Negative	100%	98.6%	98.4%	100%	100%	98.2%	100%	100%
Total	99%	98.3%	98.3%	100%	98.2%	98.3%	100%	98.3%

Specimen	MET500	MET300	MOP300	MOP200	MOP100	MPD1000	MPD300	MQL
Positive	96.9%	96.8%	96.8%	96.1%	96.1%	96.5%	97.7%	98.4%
Negative	100%	100%	97.9%	100%	100%	98.3%	98.4%	98%
Total	98.3%	98.4%	97.3%	98.1%	98.1%	97.4%	98.1%	98.2%

Specimen	MTD200	MTD200	OPI2000	OPI1000	OXY300	OXY100	PCP25	PPX
Positive	96.1%	97.3%	97.6%	96.5%	98%	96.1%	97.8%	97.8%
Negative	100%	100%	98.4%	96%	97%	100%	100%	100%
Total	98.1%	98.7%	98.1%	96.3%	97%	98.1%	98.9%	99%

Specimen	TCA	THC300	THC200	THC150	THC50	THC25	TRA	TRA100
Positive	92.1%	96.6%	96.1 %	98.4%	96.8%	96.8 %	96.6%	98.4%
Negative	100%	100%	100 %	98.3%	98.3%	98.3 %	98.2%	100%
Total	96.8%	98.4%	98.1 %	98.4%	97.5%	97.5 %	97.4%	99.1%

Specimen	ZOL
Positive	96.3%
Negative	98%
Total	97.1%

Analytical Sensitivity The sensitivity of Rapid ResponseTM Multi-Drug Test Panel (Urine) was determined by tested GC/MS confirmed controls to the concentration at negative, -50% cutoff, -25% cutoff, cutoff, +25% cutoff, +50% cutoff and 3 times of cutoff. The results are summarized below:

Drug Conc.	n	A	CE	AMP	1000	AMI	P500	AM	P300	BA	AR	В	UP	BU	IP5	BZC	500
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	19	31	16	34	14	36	20	30	11	39	25	25	21	29	12	38
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	BZC	300	BZO	200	BZO	100	COC	2300	COO	2200	COO	C150	COC	C100	HN	Ю
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	17	33	11	39	12	39	11	39	18	32	24	26	23	27	25	25
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	K	2	LS	SD	6-M	AM	C	TC	CO	Γ300	CO'	T200	EI	DDP	EDD	P100
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	14	36	22	28	25	25	15	35	17	33	13	37	24	26	25	25
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	E	ΓG	FY	L20	FY	L10	KE	T1000	K	ET300	ME	MA	MDMA	500	ME	T
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	25	25	22	28	25	25	16	34	20	30	25	25	13	37	23	27
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3 💢	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

- a			7.400		ma o o	3.60	D	3.60		3.60	D400	3.000	4000	3 (10)			~ ·
Drug Conc.	n	ME:	Γ500	ME	Г300	MO	P300	MO.	P200	MO.	P100	MPL	1000	MPI	D300	M	QL
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	10	40	15	35	18	32	18	32	20	30	24	26	22	28	14	36
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	MTI	D300	MTI	200	OPI	2000	OPI	1000	O	ΥY	OXY	7100	PC	CP	PF	PX
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	6	44	12	38	23	27	13	37	19	31	19	31	9	41	20	30
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	TO	CA	THO	2300	THO	C200	THO	C150	TH	C50	TH	C25	TF	RA	TRA	A100
(Cut-off)		-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Negative	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
50% Cut-off	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
75% Cutoff	50	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0
Cutoff	50	9	41	15	35	17	33	19	31	17	33	11	39	15	35	11	39
125% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
150% Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50
3×Cutoff	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50	0	50

Drug Conc.	n	2	ZOL
(Cut-off)		-	+
Negative	50	50	0
50% Cut-off	50	50	0
75% Cutoff	50	50	0
Cutoff	50	16	34
125% Cutoff	50	0	50
150% Cutoff	50	0	50
3×Cutoff	50	0	50

Specificity The specificity for the Rapid ResponseTM Multi-Drug Test Panel (Urine) has been tested by adding various drugs, drug metabolites, and other compounds that are likely to be present in drug-free normal human urine. The Rapid ResponseTM Multi-Drug Test Panel (Urine) performance at cutoff point is not affected when pH range of urine specimens is at 3.0 to 8.5 and specific gravity range of urine specimens is at near 1.005 to 1.03. The following compounds were found to produce positive results when tested at levels greater than the concentrations (in ng/ml) listed below, see the form in the final.

	Acetaminophen 5	000 related compounds							
Acetaminophen	5,000	Acetophenetidine	7,500						
Amphetamine 1000 related compounds									
d -Amphetamine	1,000	3,4-Methylenedioxy-methamphetamine	>100,000						
l-Amphetamine	>100,000	3,4-Methylenedioxyethylamphetamine	>100,000						
d-methamphetamine	>100,000	Paramethoxyamphetamine	625						
l-methamphetamine	>100,000	Phentermine	1,250						
3,4-Methylenedioxyamphetamine	1,250	Tyramine	>100,000						
	Amphetamine 50	00 related compounds	•						
d-Amphetamine	500	Phentermine	1,250						
l-Amphetamine	50,000	Paramethoxyamphetamine	625						
3,4-Methylenedioxyamphetamine	625	Tyramine	>100,000						
Amphetamine 300 related compounds									
d-Amphetamine	300	Phentermine	625						

l-Amphetamine	50,000	Paramethoxyamphetamine (PMA)	625
Mephentermine hemisulfate salt	>100,000	Paramethoxymethamphetamine (PMMA)	>100,00
3,4-Methylenedioxyamphetamine(MDA)	625	Tyramine	>100,00
		related compounds	1
Secobarbital	300	Butalbital	2,500
Allobarbital	1,250	Butethal	200
Alphenal	625	Cyclopentobarbital	400
Amobarbital	625	Pentobarbital	1,000
Aprobarbital	188	Phenobarbital	300
Butabarbital	94		
		10 related compound	150
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine–3–β–D–Glucuronide	10	Norbuprenorphine–3–β–D–Glucuronide	100
		5 related compounds	las
Buprenorphine	5	Norbuprenorphine	25
Buprenorphine–3–β–D–Glucuronide	_	Norbuprenorphine–3–β–D–Glucuronide	50
	500	00 related compounds	
Oxazepam		001-4-1 1-	
		00 related compounds	100.00
Oxazepam	300 125	Flurazepam	>100,00 1250
Alprazolam Bromazepam	625	Lorazepam Lormetazepam	1250
Chlordiazepoxide	2500	Medazepam Medazepam	>100,00
Chlordiazepoxide Clobazam	63	Midazolam	>100,00
Clonazepam	2500	Nitrazepam	>100,00 25000
Clorazepam	3330	Norchlordiazepoxide	25000
Ciorazepate Desalkflurazepam	250	Norchlordiazepoxide Nordiazepam	500
Desaiktiurazepam Diazepam	250	Prazepam	>100,00
Diazepam Estazolam	5000	Temazepam Temazepam	>100,00 63
Fentanyl	>100,000	Triazolam	5000
Flunitrazepam	375	Triazoiani	3000
		00 related compounds	
Oxazepam	200	Flurazepam	>100,00
Alprazolam	83	Lorazepam	833
Bromazepam	417	Lormetazepam	833
Chlordiazepoxide	1,667	Medazepam	>100,00
Clobazam	42	Midazolam	>100,00
Clonazepam	1,667	Nitrazepam	16,667
Clorazepati	2,220	Norchlordiazepoxide	167
Desalkflurazepam	167	Nordiazepam	333
Diazepam	167	Prazepam	>100,00
Estazolam	3,333	Temazepam	42
Fentanyl	>100,000	Triazolam	3,333
Flunitrazepam	250	Trazolani	5,555
		00 related compounds	<u> </u>
Oxazepam	100	Flurazepam	>100,00
Alprazolam	42	Lorazepam	417
Bromazepam	208	Lormetazepam	417
Chlordiazepoxide	833	Medazepam	>100,00
Clobazam	21	Midazolam	>100,00
Clonazepam	833	Nitrazepam	8,333
Clorazepate	1,110	Norchlordiazepoxide	83
Desalkflurazepam	83	Nordiazepam	167
Diazepam	83	Prazepam	>100,00
Estazolam	1,667	Temazepam	21
Fentanyl	>100,000	Triazolam	1,667
Flunitrazepam	125		.,
		lated compounds	
Benzoylecgonine	300	Ecgonine	100,000
Cocaine	1,000	Ecgonine Methyl Ester	>100,00
		lated compounds	
Benzoylecgonine	200	Ecgonine	5,000
Cocaine	125	Ecgonine Methyl Ester	>100,00
	-		,00
	Cocaine 150 re	lated compounds	
Benzoylecgonine	150	Ecgonine Ecgonine	10000
Cocaine	125	Ecgonine Methyl Ester	>10000
		lated compounds	F 10000
Benzoylecgonine	100		
	Cotinine 600 r	elated compounds	
(-)-Cotinine	Cotinine 600 r	elated compounds	

	Cocaine 150	0 related compounds	
Benzoylecgonine	150	Ecgonine	10000
Cocaine	125	Ecgonine Methyl Ester	>10000
	Cocaine 10	0 related compounds	
Benzoylecgonine	100		
	Cotinine 60	00 related compounds	
-)-Cotinine	600		
	Cotinine 30	0 related compounds	

Rev08-08042016 Number11110007865 Page 2 of 3

		1	
(-)-Cotinine	300	(-)-Nicotine	9,375
(-)-Cotinine	200 200 rd	elated compounds (-)-Nicotine	6,250
(-)-Cottiline		ated compounds	0,230
EDDP	100	Promazine	50,000
Meperidine	>100,000	Promethazine	25,000
Methadone	>100,000	Prothipendyl	50,000
Norfentanyl	>100,000	Prozine	12,500
Phencyclidine	>100,000		
	EDDP 300 rel	ated compounds	
EDDP	300	Promazine	80,000
Meperidine	>100,000	Promethazine	75,000
Methadone	>100,000	Prothipendyl	80,000
Norfentanyl	>100,000	Prozine	37,500
Phencyclidine	>100,000	nted compounds	
Ethyl Glucuronide	500	litea compounts	
Ethyl Glacufolide		lated compounds	
Fentanyl	10	Norfentanyl	50
	Fentanyl 20 re	lated compounds	
Fentanyl	20	Norfentanyl	375
		lated compounds	
Hydromorphone	250	Ethylmorphine	5,000
Acetylcodeine	10,000	Dihydrocodeine	25,000
Thebaine	25,000	Diacetyl Morphin	10,000
Nalorphine	12,500	Codeine	50,000
Morphine-3-glucuronid	2,500	Buprenorphine	10,000
Morphine	5,000 3,100	6-Monoacetylmorphine	10,000
Hydrocodone		ed compounds	
JWH-018-5-Pentanoic acid	50 Felau	JWH-073-4-Butanoic acid	50
		related compounds	50
Ketamine	1,000	Methadone	12,500
Norketamine	1,000	D-Methamphetamine	12,500
Dextromethorphan	500	3,4-Methylenedioxyethylamphetamine	25,000
Dextrorphan tartrate	500	Nordoxepin hydrochloride	25,000
D-Norpropoxyphene	31,250	Phencyclidine	5,000
EDDP	800	Promazine	8,000
Meperidine	12,500	Promethazine	25,000
Mephentermine hemisulfate salt	50,000		
77		related compounds	1
Ketamine	300	4-1 1-	
Lysergic acid diethylamide	50 50 rei	ated compounds	
Lysergic acid diethylannide		elated compounds	
6-Monoacetylmorphine	10	Morphine	15
		00 related compounds	1
3,4-Methylenedioxy-methamphetamine	500	3,4-Methylenedioxyamphetamine	2,500
d-Amphetamine	>100,000	3,4-Methylenedioxyethylamphetamine	156
l-Amphetamine	>100,000	Paramethoxyamphetamine	50,000
d-methamphetamine	>100,000	Paramethoxymethamphetamine	>100,000
l-methamphetamine	>100,000		
		000 related compounds	
3,4-Methylenedioxy-methamphetamine	1,000	1000 1 4 1	
		1000 related compounds	50,000
d-Methamphetamine Chloroquine	1,000	3,4-Methylenedioxyethylamphetamine	50,000 313
T 2 .	25,000	3,4-Methylenedioxy-methamphetamine	
I-Methamphetamine	12,500 10,000	(-)-Ephedrine	625 4,000
Mephentermine hemisulfate salt	31,250	() Epitedriic	4,000
		500 related compounds	
d-Methamphetamine	500	MDEA	12,500
Chloroquine	12,500	MDMA	1,875
Fenfluramine	12,500	PMMA	625
l-Methamphetamine	3,125	(-)-Ephedrine	2,000
Mephentermine hemisulfate salt	25,000	•	
	hamphetamine	300 related compounds	
d-Methamphetamine	300	MDEA	50,000
Chloroquine	7,500	MDMA	313
		PMMA	625
Fenfluramine	12,500		
	12,500 10,000 31,250	(-)-Ephedrine	2,000

	·	12,500
		12,500
		250 2,500
		25,000
		25,000
	Thebane	25,000
	0 related compounds	-
200		8,350
100	Hydromorphone	8,350
2,000	6-Monoacetylmorphine	170
170	Morphine-3-glucuronid	1,670
	Nalorphine	16,666
	Thebaine	16,666
		2 000
		2,000
		20,000
		>100,000
500		8,400
500	*	8,400
100	Trimipramine	20,000
MPD 300 re		
300		
MPD 1000	related compounds	
1000		
		50,000
		40,000
		40,000
		2 000
		2,000
		1,800
		1,000
		>100,000
		1,250
25,000		12,500
500	Nalorphine Hydrochloride	>100,000
1,250	Oxycodone	>100,000
1,563	Oxymorphone	>100,000
	Rifampicine	>100,000
	Thebaine	50,000
	related compounds	
	D valoted compounds	
		> 100 000
		>100,000 750
	Oxymorphone	730
	00 related compounds	-
100	Naloxone	50,000
25,000		250
50,000		
	25 related compounds	·
	Hydromorphone	6,250
12,500	4-hydroxyphencyclidine	75
300		5,000
1,000	Nordoxepin	500
1 500	Opipramol	1,563
1,500		
>100,000	Promazine	1,000
>100,000 12,500	Promethazine	6,250
>100,000 12,500 188	Promethazine Prothipendyl	6,250 25,000
>100,000 12,500 188 2,000	Promethazine Prothipendyl Protryptyline	6,250 25,000 6,250
>100,000 12,500 188 2,000 2,500	Promethazine Prothipendyl Protryptyline Prozine	6,250 25,000 6,250 1,250
>100,000 12,500 188 2,000 2,500 750	Promethazine Prothipendyl Protryptyline	6,250 25,000 6,250
	300 150 3,125 250 250 586 200 Morphine 20 200 100	150

	Marijuana 30	00 related compounds	
1-nor-Δ9-THC-9-COOH	300		
	Marijuana 15	0 related compounds	
11-nor-Δ9-THC-9-COOH	150	Δ9-Tetrahydrocannabinol	45,000
11-nor-Δ8-THC-9-COOH	90	Cannabinol	60,000
Δ8-Tetrahydrocannabinol	45,000		
	Marijuana 5	0 related compounds	
1-nor-Δ9-THC-9-COOH	50	Δ9-Tetrahydrocannabinol	15,000
1-nor-Δ8-THC-9-COOH	50	Cannabinol	20,000
1-hydroxy-Δ9-Tetrahydrocannabinol	50	Cannabidiol	>100,000
8-Tetrahydrocannabinol	15,000		
	Marijuana 2	5 related compounds	•
1-nor-Δ9-THC-9-COOH	25	Δ9-Tetrahydrocannabinol	7,500
1-nor-Δ8-THC-9-COOH	15	Cannabinol	10,000
8-Tetrahydrocannabinol	7,500		
	Tramadol 30	0 related compounds	
`ramadol	300		
	Tramadol 10	0 related compounds	
`ramadol	100	Diphenhydramine	50,000
+/-)Chlorpheniramine	50,000	Phencyclidine	50,000
Dimenhydrinate	50,000	(+)-Chlorpheniramine	>100,000
	Zolpidem 50	0 related compounds	
Colpidem	50	_	

The following compounds were found not to cross-react when tested at concentrations at 100 µg/ml. (-)-Ephedrine (Except MET) Chlorpheniramine (+)-Naproxen Creatine Penicillin-G (+/-)-Ephedrine (Except MET) Dextromethorphan Pheniramine 4-Dimethyllaminoantiyrine Dextrorphan tartrate Phenothiazine Acetaminophen (Except ACE) Dopamine L-Phenylephrine Acetone Erythromycin Procaine

Albumin Ethanol Protonix Amitriptyline (Except TCA) Furosemide Pseudoephedrine Ampicillin Glucose Quinidine Guaiacol Glyceryl Ether Ranitidine Aspartame Hemoglobin Sertraline Aspirin Atropine Ibuprofen Tyramine

 Benzocaine
 Imipramine (Except TCA)
 Vitamin C (Ascorbic Acid)

 Bilirubin
 (+/-)-Isoproterenol
 Trimeprazine

 b-Phenylethyl-amine
 Lidocaine
 Venlafaxine

 Caffeine
 Methadone (Except MTD)
 Ibuprofen

Chloroquine N-Methyl-Ephedrine

LITERATURE REFERENCES

- 1. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd ed. Davis: Biomedical Publications; 1982.
- Hawks RL, Chiang CN, eds. Urine Testing for Drugs of Abuse. Rockville: Department of Health and Human Services, National Institute on Drug Abuse; 1986.
- Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs. 53 Federal Register; 1988.
- 4. McBay AJ. Drug-analysis technology--pitfalls and problems of drug testing. Clin Chem. 1987 Oct; 33 (11 Suppl): 33B-40B.
- Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan; 1980.

GLOSSARY OF SYMBOLS

SVT/Adulterant Color Chart

Abnormal	Abnormal	Ш	OX PCC	Oxidants/Pyridinium chlorochromate		NIT	Nitrite
Normal	Normal	Ш	S.G.	Specific gravity	П	GLUT	Glutaraldehyde
			pН	pH		CRE	Creatinine

Index of Symbols

<u>i</u>	Consult instructions for use	Σ	Tests per kit	EC REP	Authorized Representative
	For in vitro diagnostic use only	\square	Use by	2	Do not reuse
2.c	Store between 2-30°C	LOT	Lot Number	REF	Catalog #

BTNX Inc. 570 Hood Road, Unit 23 Markham, ON, L3R 4G7, Canada Technical Support: 1-888-339-9964



Rev08-08042016 Number11110007865 Page 3 of 3